Researchers from China developed a radiomics model that can help predict the survival rate of patients as well as determine the malignancy of lymph node metastases in patients with bile duct cancer by analyzing features on CT scans. The radiomics model accurately identified more malignant lymph node metastases than any other standard method. Patients’ estimated risk of cancer recurrence after surgery was predicted with a diagnostic accuracy of 74 percent. Radiomics could have prevented a large number of misclassifications and have the potential to reduce biopsies which are challenging in this particular type of disease.
Read the full article here
According to scientists from the National Institute for Nuclear Physics, radiomics approaches will have a bright future particularly when multidisciplinary teams work collaboratively.
Dr. Robert Gillies of Moffitt Cancer Center is often called the ‘Father of Radiomics’ and predicts that radiomics is the next frontier in clinical decision making, noting that “radiomics appears to offer a nearly limitless supply of imaging biomarkers that could potentially aid cancer detection, diagnosis, assessment of prognosis, prediction of response to treatment, and monitoring of disease status.” As a lead advisor, Dr. Gillies helped HealthMyne develop the first software platform in the world that can extract radiomic features in the standard clinical workflow.